Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor.

about

Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor.

Item

http://www.wikidata.org/entity/Q40519438

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Charlson comorbidity index pre ...... ith tyrosine kinase inhibitor.

@en

type

Item

label

Charlson comorbidity index pre ...... ith tyrosine kinase inhibitor.

@en

prefLabel

Charlson comorbidity index pre ...... ith tyrosine kinase inhibitor.

@en

P1476

Charlson comorbidity index pre ...... ith tyrosine kinase inhibitor.

@en

P2093

Akihito Matsuoka

http://www.w3.org/2001/XMLSchema#string

Kimihiro Kawakami

http://www.w3.org/2001/XMLSchema#string

Makiko Uemura

http://www.w3.org/2001/XMLSchema#string

Norimitsu Kadowaki

http://www.w3.org/2001/XMLSchema#string

Osamu Imataki

http://www.w3.org/2001/XMLSchema#string

Yasunori Kawachi

http://www.w3.org/2001/XMLSchema#string

Yasuo Hoshijima

http://www.w3.org/2001/XMLSchema#string

P2860

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

Decreasing trend in mortality of chronic myelogenous leukemia patients after introduction of imatinib in Japan and the U.S.

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

How I treat newly diagnosed chronic phase CML

P2888

s12185-016-2074-3

P304

621-627

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12185-016-2074-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27492732

http://www.w3.org/2001/XMLSchema#string